Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational Clinical Trial to Evaluate PLX cells for the Treatment of Patients Suffering from Complications Associated with COVID-19

Next Previous
Trial Profile

A Multinational Clinical Trial to Evaluate PLX cells for the Treatment of Patients Suffering from Complications Associated with COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COVID-19 infection therapeutics Charite University of Medicine Berlin/Pluristem Therapeutics (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Pluri

    • Most Recent Events

    • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
    • 05 May 2020 According to an Pluristem Therapeutics media release, the company announced that it has entered into definitive agreements with two institutional investors in connection with a registered direct offering. The company intends to use the net proceeds from the offering for working capital, including funding towards its Phase II study of PLX cell therapy in the treatment of complications arising from COVID-19 and other clinical trial activities.
    • 24 Apr 2020 According to a Pluristem Therapeutics media release, as the company moves forward into this multinational clinical trial for PLX cells to treat patients suffering from complications associated with COVID-19, it expects the EIB financing (Euro 50 million non-dilutive financing) will accelerate the path to approval and to making a potentially effective COVID-19 treatment available worldwide.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top